Press Releases

BOSTON, MA – September 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of Thomas Kester to the Company’s Board of Directors and Chairman of the Company’s Audit Committee. Mr. Kester brings over 40… Read More

 Company to Host Conference Call Today at 4:30pm ET BOSTON, MA – August 9, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced financial and operating results for the second quarter ended June 30, 2016, and provided… Read More

BOSTON, MA – August 2, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2016 on Tuesday, August 9 after the market close, followed by a conference call at 4:30 p.m. ET to review… Read More

BOSTON, MA – August 1, 2016 — InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced the listing of the Company’s 44,242,424 previously issued warrants on the NYSE MKT (the “Exchange”).  Beginning at the market open on August 1,… Read More

BOSTON, MA – July 21, 2016 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced that the NYSE MKT (the “Exchange”) has notified the Company that it has regained compliance with the NYSE MKT continued listing standards. InspireMD received… Read More

BOSTON, MA – July 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the closing of a “best efforts” public offering of 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to… Read More

BOSTON, MA – June 30, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the pricing of a “best efforts” public offering of approximately 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up… Read More

Principal Payments Deferred, Assisting Cash Management Programs   BOSTON, MA – June 14, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that it has completed a restructuring of its existing debt. The Company restructured its term loan… Read More

Medical Device Veteran Brings Broad Industry Experience in Pioneering Technologies BOSTON, MA – June 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of James Barry, Ph.D. as President and CEO effective immediately.  Prior to… Read More

BOSTON, MA – May 17, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuardTM EPS reported positive results in PARADIGM-101, an investigator led clinical evaluation of the system for routine use in 101 consecutive, increased risk… Read More